Implant device for chemo delivery in advanced pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests an implantable device that delivers chemotherapy (gemcitabine) directly to pancreatic tumors. It may offer a new treatment option for people with non-metastatic, advanced pancreatic cancer that cannot be surgically removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic cancer that hasn't spread to other parts of your body and cannot be removed by surgery.
- You are well enough to perform daily activities without much help (ECOG score 0 or 1).
- You have previously received standard chemotherapy like FOLFIRINOX or Gemcitabine plus Abraxane.
- You do not have severe pancreatitis currently.
- You have not had radiation therapy for your pancreatic cancer.
- You have no history of heart disease affecting heart function or any metal implants.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a non-invasive device that uses low-level radio waves to standard chemotherapy (gemcitabine and nab-paclitaxel) can help people with pancreatic cancer that has spread to other parts of the body.
This trial tests a tiny implantable device that measures how different chemotherapy drugs work on your tumor during surgery. The goal is to find the most effective treatment for your specific cancer.
This trial tests a new immunotherapy drug (ivonescimab) combined with targeted radiation and chemotherapy for people with pancreatic cancer. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial studies NovoTTF-200T(P), a portable treatment device, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with resectable pancreatic adenocarcinoma. It aims to improve treatment results by trying this combination before surgery.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Hear when a new Pancreatic Adenocarcinoma Non-resectable trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.